SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022
Deprescribing in palliative patients with cancer: a concise review of tools and guidelines.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Deprescribing decisions in palliative care: a qualitative meta-synthesis of multi-stakeholder experiences and influencing factors.BMC palliative care · 2026Pooled it
- Deprescribing for Comorbidities in Patients with Cancer - a Systematic Review.Current oncology reports · 2026Pooled it
- Barriers and facilitators of deprescribing for older adults with cancer and polypharmacy.Journal of geriatric oncology · 2026Article
- Antithrombotic therapy at the end-of-life-continue or stop?Research and practice in thrombosis and haemostasis · 2026Review
- Real-world patterns of cardiovascular medication use in the final 28 days of life among patients with advanced cancer: a retrospective analysis by hospice care type.BMC palliative care · 2025Article
- Shared decision-making and deprescribing to support anti-thrombotic therapy (dis)continuance for persons living with cancer in their last phase of life: A realist synthesis.PLoS medicine · 2025Article
- Medication Prescriptions for Chronic Diseases in Terminal Cancer Patients in Korea: A Real-World Study.Journal of hospice and palliative care · 2025Article
- Polypharmacy driven synergistic toxicities in elderly breast cancer chemotherapy drug management and adverse drug reactions: a mini review.Frontiers in pharmacology · 2025Review
- Trends in prescriptions and factors associated with discontinuation of potentially inappropriate medications in elderly patients with advanced cancer at the end of life: A retrospective cohort study.Palliative care and social practice · 2025Article
- Appropriate medication use in Dutch terminal care: study protocol of a multicentre stepped-wedge cluster randomized controlled trial (the AMUSE study).BMC palliative care · 2024Article
- DEprescribing: Perceptions of PAtients living with advanced cancer. A multicentre, prospective mixed observational study protocol.PloS one · 2024Article
- Optimizing pharmacotherapy and deprescribing strategies in older adults living with multimorbidity and polypharmacy: EuGMS SIG on pharmacology position paper.European geriatric medicine · 2023Article
- Deprescribing: A Prime Opportunity to Optimize Care of Cancer Patients.Current oncology (Toronto, Ont.) · 2023Review
- Perspectives on deprescribing in palliative care.Expert review of clinical pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePalliative cancer patients can benefit from deprescribing of potentially inappropriate medications (PIMs). Tools and guidelines developed for the geriatric population are mainly available. This systematic review gives an overview of available guidelines and tools to deprescribe for palliative cancer patients.
methodsA systematic search was carried out using the databases SCOPUS and PubMed. Studies focused on palliative cancer patients were included.
resultsThe search identified 137 studies of which 15 studies were included in this systematic review. Six of the included tools were developed specifically for cancer patients. One of these tools was externally validated and applied in several studies and settings. Guidelines or tools that were not specifically developed for cancer patients but that were applied on cohorts of palliative cancer patients were also included.
conclusionTools developed for geriatric patients contain drugs that are not inappropriate when used in the palliative cancer care setting. Tools developed for cancer patients are more suitable and can be applied in combination with stepwise methods to individualize deprescribing per patient. The tools and guidelines described in this systematic review can be used to further implement deprescribing in the clinical routine for palliative cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.